Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cilo Cybin HoldingsJSE:CCC 7 EBITDA Margin % is -1,139.93% as of Sep. 2025. GuruFocus rates JSE:CCC with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 961 Drug Manufacturers companies, Cilo Cybin Holdings ranks worse than 96.77% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cilo Cybin Holdings's EBITDA for the
six
months ended in Sep. 2025 was R-211.44 Mil. Cilo Cybin Holdings's Revenue for the
six
months ended in Sep. 2025 was R18.55 Mil. Therefore, Cilo Cybin Holdings's EBITDA margin for the quarter that ended in Sep. 2025 was -1,139.93%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cilo Cybin Holdings EBITDA Margin % Related Terms
Cilo Cybin Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cilo Cybin Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:CCC vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cilo Cybin Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cilo Cybin Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cilo Cybin Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cilo Cybin Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cilo Cybin Holdings (JSE:CCC) has a EBITDA Margin % of -1,139.93% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cilo Cybin Holdings and its competitors. According to the industry distribution chart, Cilo Cybin Holdings ranks #930 out of 961 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Cilo Cybin Holdings' EBITDA Margin % too high?
Cilo Cybin Holdings' current EBITDA Margin % is -1,139.93%. Based on the distribution chart, Cilo Cybin Holdings ranks #930 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cilo Cybin Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Cilo Cybin Holdings' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cilo Cybin Holdings ranks #930 out of 961 companies for EBITDA Margin %. This places Cilo Cybin Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cilo Cybin Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cilo Cybin Holdings's current EBITDA Margin % is -1,139.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cilo Cybin Holdings stock overvalued right now?
Cilo Cybin Holdings (JSE:CCC) has a current EBITDA Margin % of -1,139.93%. The current EBITDA Margin % is -1,139.93%. Cilo Cybin Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cilo Cybin Holdings (JSE:CCC), the current EBITDA Margin % is -1,139.93% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cilo Cybin Holdings Ltd is engaged in identifying viable investments in Biotech, Biohacking and Pharmaceutical businesses. It offers products and services in the medical cannabis sector.
7GF Score
Get the complete analysis for JSE:CCC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:CCC has been successfully added to your 
